The Effect of Glucuronidation on Curcumin Bioactivity in Bone Metastatic Breast Cancer
PublisherThe University of Arizona.
RightsCopyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.
AbstractBreast cancer bone metastasis is characterized by the formation of osteolytic lesions via a TGFβ-dependent vicious cycle. Although there is currently no cure for these lesions, previous studies show that turmeric-derived curcuminoids (CURC) may inhibit this pathway in estrogen receptor negative (ER–) breast cancers. However, most circulating CURC exists in its glucuronidated form (G-CURC), so this study sought to determine the effects of glucuronidation on CURC bioactivity in multiple ER– breast cancer cell lines. The results reveal that CURC decreases phosphorylation of Smad proteins, a key step in the TGFβ signaling pathway, in multiple ER– breast cancer cell lines, while G-CURC has no effect. Furthermore, secretion of TGFβ-induced parathyroid hormone-related protein (PTHrP), a key osteolytic factor in bone metastasis, was inhibited in ER– cells lines following CURC treatment and subsequent TGFβ stimulation. These data suggest that aglycone CURC inhibits the Smad-dependent TGFβ signaling pathway involved in the breast cancer bone metastases and may prevent release of osteolytic factors that aid in bone resorption, while G-CURC is not biologically active. Since GCURC is the predominate form in circulation, future studies are necessary to characterize the means through which G-CURC may be converted to CURC, systematically and/or within the bone microenvironment.
Degree ProgramHonors College